Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

ATB200-02: Phase I/II

Treating: Pompe Disease
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III

Treating: Axial Spondyloarthritis
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling

A randomized, double-blind, placebo-controlled multicenter
study of secukinumab to evaluate the safety, tolerability
and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CIRT: Cardiovascular Inflammation Reduction Trial

Treating: Cardiac
Status: Open and Currently Enrolling

A randomized, double-blind placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

CLEE011A2404: Phase IIIb

Treating: Advanced Breast Cancer
Indication: Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer
Status: Open and Currently Enrolling
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

D1699C00001: Phase III

Treating: Heart Failure
Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction


Treating: Cardiac

Treating: Cardiac
Status: Not Currently Enrolling

A multicenter, randomized, double blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes.

DIV-SCLC-301: Phase II/III

Treating: Lung Cancer
Indication: Small Cell Lung Cancer
Status: Open/Currently Enrolling

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

Meet Our Providers

Andrea Withey, RDN


Erica Bonilla, DPT

Physical Therapy

Robert Henderson, MD


Internal Medicine

Becky Wozniak, DNP

Family Practice